Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Anatomic Stage IV Breast Cancer AJCC v8

Neoplasm Metastasis, Neoplasms

Advanced Metastatic Breast Cancer

Breast Neoplasms

Advanced Breast Carcinoma

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Hormone Receptor Positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Advanced Cancer

Breast Neoplasms, Neoplasms

Lymphoma, Non-Hodgkin

Advanced Breast Cancer

Neoplasm Metastasis

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Lethal Congenital Contracture Syndrome 2

Clinical Trials

CONFIRM

VERITAC-2

INAVO120

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

FALCON

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

AMEERA-3

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

MONARCH plus

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

postMONARCH

BYLieve

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

A Study of TAS-120 in Patients With Metastatic Breast Cancer

MORPHEUS HR+BC

MONARCH 2

Palbociclib After CDK and Endocrine Therapy (PACE)

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

EMERALD

EMBER-3

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

B-PRECISE-01

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

SoFEA

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

ASPIRE

SOLAR-1

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

PARSIFAL

MAINTAIN

monarcHER

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

IPATunity150

EPIK-B4

PEARL

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

TELEPIK

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

SUMMIT

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.